Higher serum IL-1β levels independently predicted long-term all-cause mortality in ambulatory patients with idiopathic dilated cardiomyopathy (HR 1.193; 95% CI 1.056-1.349; p=0.005).
Cohort (n=156)
Do serum levels of IL-1β predict long-term mortality and need for heart transplantation in ambulatory patients with idiopathic dilated cardiomyopathy?
Serum IL-1β levels serve as an independent predictor of long-term mortality and the need for heart transplantation in patients with idiopathic dilated cardiomyopathy.
Estimación del efecto: HR 1.193 (95% CI 1.056 - 1.349)
valor p: p=0.005
AIMS: The prognostic stratification of patients with Idiopathic Dilated Cardiomyopathy (iDCM) is a difficult task. Here, we assessed the additive value of the evaluation of biomarkers of inflammasome activation and systemic inflammation for the long-term risk stratification of iDCM patients. METHODS AND RESULTS: We studied 156 ambulatory iDCM patients (mean age 58 years, 77% men, 79% in NYHA class 1-2, median Left Ventricular Ejection Fraction (LVEF) 35%, mean sodium 139 mEq/L, median BNP 189 pg/mL, median IL-1 beta (IL-1β) 1.08 pg/mL, median IL-6 1.7 pg/mL and median IL-10 2.7 pg/mL).During the follow-up period of 89.6 months, 35 patients (22%) died/underwent heart transplantation. Patients who died/underwent heart transplantation were more likely to be male, to be in NYHA class III, to have atrial fibrillation, to have lower LVEF and higher BNP levels. IL-1β, IL-6 and IL-10 levels did not differ significantly between the groups of patients with good or bad prognosis. IL-1β levels did not vary significantly among either the different NYHA classes or the quartiles of LVEF. In a multivariable model, however, IL-1β was a strong and independent predictor of all-cause mortality (HR 1.193, 95% CI 1.056 - 1.349, p=0.005 for log squared transformed values). Other factors associated with the outcome were: male gender, presence of atrial fibrillation and sodium concentration. The estimated time-dependent ROC curve of the multivariable model showed an AUC 0.74 (95% CI 0.65-0.86). CONCLUSIONS: Serum levels of IL-1β could be useful to predict the long-term outcome of patients with iDCM.
Aleksova et al. (Wed,) conducted a cohort in Idiopathic Dilated Cardiomyopathy (iDCM) (n=156). IL-1β levels was evaluated on All-cause mortality (HR 1.193, 95% CI 1.056 - 1.349, p=0.005). Higher serum IL-1β levels independently predicted long-term all-cause mortality in ambulatory patients with idiopathic dilated cardiomyopathy (HR 1.193; 95% CI 1.056-1.349; p=0.005).